Ro-41-1049 is a small-molecule, reversible, and selective inhibitor of human monoamine oxidase A (MAO-A), originally developed by Roche. It binds with high affinity to MAO-A in human frontal cortex (Kd ~16.5 nM) and placenta (Kd ~64.4 nM), acting as an orally active MAO-A inhibitor that has been used in biochemical research to probe MAO-A function.